Page 64 - 2022_01-Haematologica-web

A. Khalil et al.
Funding
This work was supported by the Deutsche José Carreras Leukämie-Stiftung e.V. (DJCLSR 13/01). The monitoring of PEG-ASNase activities and of antibodies against PEG-ASNase and native E. coli ASNase was supported by Servier (Suresnes, France), Shire (Lexington, USA), Baxalta (Westlake Village, USA), Sigma Tau Pharmaceuticals (Zofingen, Switzerland) and medac GmbH (Wedel, Germany). In Australia, ASNase monitor- ing and the collection of samples for antibody determination for the
AIEOP-BFM ALL 2009 trial were funded by the Kids Cancer Alliance (KCA), a Translational Cancer Research Center of the Cancer Institute of New South Wales (15/TRC/1-04). CN is supported by the Leukemia Research and Support Fund at The Children’s Hospital at Westmead (Australia). In Austria monitor- ing of ASNase activity and collection of samples for antibody determination for the AIEOP-BFM ALL 2009 trial were funded by the St. Anna Kinderkrebsforschung (BFM-Austria). The work is part of the thesis of AK.
References
1. Fruijtier-Pölloth C. Safety assessment on polyethylene glycols (PEGs) and their deriv- atives as used in cosmetic products. Toxicology. 2005;214(1-2):1-38.
2. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethyl- ene glycol)-protein conjugates. Adv Drug Deliv Rev. 2003;55(10):1261-1277.
3. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214-221.
4. Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351- 367.
5. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treat- ment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008;60(1):59-68.
6. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991-998.
7. Barnard DL. Pegasys (Hoffmann-La Roche). Curr Opin Investig Drugs. 2001;2(11):1530- 1538.
8. Graham ML. Pegaspargase: a review of clin- ical studies. Adv Drug Deliv Rev. 2003;55(10):1293-1302.
9. Pieters R, Hunger SP, Boos J, et al. L-asparag- inase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238-249.
10. Hunger SP, Mullighan CG. Acute lym- phoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552.
11. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L- asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05- 001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677-1690.
12. Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther. 2009;9(1):111-119.
13. Rytting M. Peg-asparaginase for acute lym- phoblastic leukemia. Expert Opin Biol Ther. 2010;10(5):833-839.
14. Yang Q, Lai SK. Anti-PEG immunity: emer- gence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(5):655-677.
15. Poppenborg SM, Wittmann J, Walther W, et al. Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice. Eur J Pharm Sci. 2016;91:122-130.
16. Ishida T, Kashima S, Kiwada H. The contri- bution of phagocytic activity of liver macrophages to the accelerated blood clear- ance (ABC) phenomenon of PEGylated lipo-
somes in rats. J Control Release. 2008;126
(2):162-165.
17. Myler H, Hruska MW, Srinivasan S, et al.
Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-g-1a and PEG-IFN- a2a in naive patients. Bioanalysis. 2015;7(9):1093-1106.
18. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8(1):R12.
19. Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre- existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ trans- plant recipients. Arthritis Res Ther. 2014;16 (2):R63.
20.U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products. https://www.fda.gov/regulatory- information/search-fda-guidance-docu- ments/immunogenicity-assessment-thera- peutic-protein-products. Accessed 11.11.2020
Res. 2016;33(9):2239-2249.
29. Chen B-M, Su Y-C, Chang C-J, et al.
Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal Chem. 2016;88 (21):10661-10666.
30.Yang Q, Jacobs TM, McCallen JD, et al. Analysis of pre-existing IgG and IgM anti- bodies against polyethylene glycol (PEG) in the general population. Anal Chem. 2016;88(23):11804-11812.
31.Ganson NJ, Povsic TJ, Sullenger BA, et al. Pre-existing anti-polyethylene glycol anti- body linked to first-exposure allergic reac- tions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol. 2016;137(5):1610-1613.
32. Tillmann H, Ganson NJ, Patel K, et al. High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-interferon. J Hepatol. 2010;52:S129.
33.Henriksen LT, Nersting J, Raja RA, et al. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 2014;166(2):213- 220.
21. 22.
Parenky A, Myler H, Amaravadi L, et al. New FDA draft guidance on immunogenici- ty. AAPS J. 2014;16(3):499-503.
Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110(1):103-111.
23.Liu Y, Smith CA, Panetta JC, et al. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37(23):2051-2061.
24. van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparagi- nase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279-285.
25. Asselin B, Rizzari C. Asparaginase pharma- cokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56 (8):2273-2280.
26. Richter AW, Akerblom E. Polyethylene gly- col reactive antibodies in man: titer distribu- tion in allergic patients treated with monomethoxy polyethylene glycol modi- fied allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol. 1984;74(1):36-39.
27. Liu Y, Reidler H, Pan J, et al. A double anti- gen bridging immunogenicity ELISA for the detection of antibodies to polyethylene gly- col polymers. J Pharmacol Toxicol Methods. 2011;64(3):238-245.
28. Lubich C, Allacher P, de la Rosa M, et al. The mystery of antibodies against polyethylene glycol (PEG) - what do we know?. Pharm
35. Tong WH, Pieters R, Kaspers GJL, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123(13):2026-2033.
36. Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2017;58(3):540-551.
37.Willer A, Gerss J, König T, et al. Anti- Escherichia coli asparaginase antibody levels determine the activity of second-line treat- ment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood. 2011;118(22):5774-5782.
38. Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr Opin Immunol. 1995;7(3):349-354.
39. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-indepen- dent manner. J Control Release. 2007;122(3): 349-355.
40. Mima Y, Hashimoto Y, Shimizu T, Kiwada H, Ishida T. Anti-PEG IgM is a major con- tributor to the accelerated blood clearance of polyethylene glycol-conjugated protein. Mol Pharm. 2015;12(7):2429-2435.
41. Marini BL, Perissinotti AJ, Bixby DL, Brown
34.
Henriksen LT, Harila-Saari A, Ruud E, et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015;62(3):427-433.
56
haematologica | 2022; 107(1)